Announcements Trials

Browse Landscape

Phase

Phase 2 5 Phase 1 3 Phase EARLY_PHASE1 2 Phase 3 1 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 6 Genitourinary 4 Gastrointestinal 3 Breast 3 Thoracic 2 Other solid neoplasm 2 Tumor-Agnostic 1 Head & Neck 1 CNS 1

Conditions

Interventions

Temozolomide 102 Radiotherapy 47 Bevacizumab 33 Carboplatin 23 Irinotecan 20 pembrolizumab 17 Radiosurgery 16 Nivolumab 16 Radiation 14 Cyclophosphamide 11 Magnetic Resonance Spectroscopy 10 fludarabine 8 Trastuzumab 8 Radiotherapy, Intensity-Modulated 8 Carmustine 8 Surgical Procedures, Operative 7 Specimen Handling 7 Pemetrexed 7 Paclitaxel 7 Interleukin-2 7 Filgrastim 7 Everolimus 7 Erlotinib Hydrochloride 7 temsirolimus 6 Vorinostat 6 Radiotherapy, Conformal 6 Lomustine 6 Ipilimumab 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 Gemcitabine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × niraparib × CNS × Clear all

NCT06258018 2024-08-30

ONC-2022-001

Istituto Clinico Humanitas

Phase 1/2 Not yet recruiting

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡